Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tecovirimat - SIGA Technologies

Next Previous
Drug Profile

Tecovirimat - SIGA Technologies

Alternative Names: Arestvyr; SIGA-246; ST-246 Form I (monohydrate); ST-246 Form V (hemihydrate); ST-246®; Tecovirimat monohydrate - SIGA Technologies; TPOXX

Latest Information Update: 11 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ViroPharma
  • Developer National Institute of Allergy and Infectious Diseases; SIGA Technologies
  • Class Antivirals; Benzamides; Cyclopropanes; Fluorinated hydrocarbons; Isoindoles; Organic bridged compounds; Small molecules
  • Mechanism of Action Orthopoxvirus p37 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Smallpox; Orthopoxvirus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Smallpox
  • Registered Monkeypox; Orthopoxvirus infections; Vaccinia

Most Recent Events

  • 31 Dec 2023 SIGA technologies completes a clinical trials in Monkeypox (In adults, In children, In adolescents) in UK (PO)
  • 12 May 2023 SIGA Technologies completes a phase III trial (In volunteers) (PO, Capsule) in the US (NCT04971109)
  • 05 May 2023 SIGA Technologies completes a phase II drug-vaccine interaction study (In volunteers) in USA (PO) (NCT04957485)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top